Abstract
Heart failure, a pressing issue in modern cardiology, occurs with preserved ejection fraction in more than 50% of cases. Screening and risk factor modification in HFpEF can be an effective strategy for improving long-term patient outcomes. One of the important components of such a strategy is hypertension control. Modern studies have shown that pharmaceutical control aimed not only at lowering baseline BP but also at minimizing its long-term impact leads to additional benefits for the patient, reducing cardiovascular morbidity and mortality, as well as the frequency of hospital readmissions. Our review reveals a method for calculating an indicator demonstrating the long-term impact of BP in heart failure and its clinical significance